Protara Therapeutics’ (TARA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Protara Therapeutics (NASDAQ:TARA) in a report issued on Thursday morning,Benzinga reports. They currently have a $23.00 price objective on the stock. HC Wainwright also issued estimates for Protara Therapeutics’ FY2029 earnings at ($0.73) EPS.

Separately, Guggenheim reaffirmed a “buy” rating and set a $20.00 price target on shares of Protara Therapeutics in a research report on Friday, December 6th.

Protara Therapeutics Trading Up 2.6 %

Shares of TARA opened at $4.02 on Thursday. Protara Therapeutics has a twelve month low of $1.60 and a twelve month high of $10.48. The firm has a market capitalization of $82.93 million, a P/E ratio of -1.43 and a beta of 1.69. The firm’s 50-day moving average is $4.56 and its two-hundred day moving average is $3.42.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.09. Analysts predict that Protara Therapeutics will post -3.32 EPS for the current year.

Institutional Investors Weigh In On Protara Therapeutics

A number of large investors have recently added to or reduced their stakes in TARA. XTX Topco Ltd bought a new position in Protara Therapeutics during the 3rd quarter valued at $60,000. HBK Investments L P bought a new stake in Protara Therapeutics in the 4th quarter valued at about $106,000. Squarepoint Ops LLC acquired a new position in Protara Therapeutics during the 4th quarter valued at about $110,000. Dimensional Fund Advisors LP acquired a new position in Protara Therapeutics during the 4th quarter valued at about $111,000. Finally, Bailard Inc. acquired a new position in Protara Therapeutics during the 4th quarter valued at about $157,000. 38.13% of the stock is owned by institutional investors and hedge funds.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.